NYKD — Nykode Therapeutics ASA Share News
0.000.00%
- NOK870.25m
- NOK450.97m
Brief: Nykode Therapeutics To Regain Control Of VB10.Neo Program
Europe Research Roundup: Draegerwerk, Hikma, Novartis
Brief: Nykode Therapeutics Q2 Operating Loss Of $11.8 Mln
Brief: Nykode Therapeutics Announces Strategic Repositioning Of VB10.16
Brief: Nykode Therapeutics: Issuance Of Key Patent Covering Individualized Neoantigen Based Vaccines
Brief: Nykode Therapeutics: mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
Brief: Nykode Therapeutics Initiates Phase 2 Trial Of Vb10.16
Brief: Nykode Therapeutics CEO Acquires 6,000 Shares In Co
Brief: Nykode Q4 Net Loss $5.3 Million
Brief: Nykode Therapeutics Q3 Net Loss Narrows To $10.2 Million
Brief: Bookrunner Says Nykode Primary ABB Books Are Covered; Indicated Demand Exceeds The Deal Size
Brief: Nykode Therapeutics Provides Update On Process With The Norwegian Tax Authorities
Brief: Nykode Therapeutics Initiates Phase 1/2A Trial Of VB10.16
Brief: Nykode Says On-Track To Leverage Phase 2 Cervical Cancer Data
Brief: Nykode Therapeutics Announces FDA Approval Of Phase 2 Clinical Trial
Brief: Nykode Q2 Operating Loss $11.9 Million
Brief: Nykode Therapeutics Q1 Net Loss Widens To USD 10.4 Mln
Brief: Nykode Therapeutics Announces Positive Final Results From Its Phase 2 Trial Of Vb10.16 In Combination With Pd-L1 Inhibitor Atezolizumab In Advanced Cervical Cancer
Brief: Nykode Therapeutics Announces Positive Final Results From Phase 2 VB-C-02 Trial